How a new medicine is tested in each trial phase and why it can still fail

A new medicine must clear four distinct trial phases before regulators can sign off, and each stage tests a different question, meaning a drug that sails through Phase I can still stumble in Phase III.

Phase I: safety and dosage

Phase I is the first time a drug is given to humans. The primary goal is to see whether it is safe and to determine the appropriate dose range. Trials usually enroll a small group of healthy volunteers – often between 20 and 100 people – and monitor them closely for adverse reactions. Researchers also collect basic pharmacokinetic data, such as how quickly the drug is absorbed and cleared.

Phase II: efficacy and side‑effects

If Phase I shows an acceptable safety profile, the sponsor moves to Phase II, where the focus shifts to whether the drug actually works for the intended disease. These studies involve several hundred patients who have the condition. They are usually randomised and may be double‑blind, allowing scientists to compare the experimental drug against a placebo or an existing therapy. In addition to efficacy signals, Phase II gathers more detailed safety information, especially side‑effects that might only appear at therapeutic doses.

Phase III: large‑scale confirmation

Success in Phase II earns a drug a go‑ahead for Phase III, the most expansive and expensive stage. Thousands of participants across multiple countries are recruited, often in a series of parallel studies. The aim is to confirm efficacy, monitor rare adverse events, and provide the statistical power needed for regulatory approval. In the United States, the FDA typically expects at least two successful Phase III trials before granting marketing authorization, though there are exceptions for breakthrough therapies.

Phase IV: post‑marketing surveillance

Even after a drug is approved, its story isn’t over. Phase IV studies, sometimes called post‑marketing surveillance, track the medicine in real‑world use. These investigations can last years and may involve millions of patients. They are crucial for spotting rare or long‑term side‑effects that weren’t evident in earlier trials. If significant safety concerns emerge, regulators can issue new warnings, restrict use, or even withdraw the product.

Why a drug can pass one phase and fail the next

Each phase asks a distinct question. A compound might be perfectly safe in a small group of healthy volunteers (Phase I) but prove ineffective in patients with the disease (Phase II). Conversely, a drug could show promising efficacy in a few hundred patients yet reveal serious, infrequent adverse events when exposed to a larger, more diverse population in Phase III. The statistical thresholds also differ: early phases tolerate higher uncertainty, while Phase III demands robust, reproducible results.

Regulators weigh the totality of evidence – safety, efficacy, and the benefit‑risk balance – before granting approval. That is why a drug can be celebrated after Phase II and still face a setback in the final trial, or why a product that reaches the market can later be pulled after Phase IV data raise new concerns.

Understanding these stages helps patients, investors and policymakers appreciate why drug development is both lengthy and risky, and why not every promising candidate makes it to the pharmacy shelf.